^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EGFR mutation + ALK mutation

    i
    Other names: NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor, EGFR, ERBB, ERBB1, Epidermal growth factor receptor
    Entrez ID:
    1956; 238
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    1m
    Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC (clinicaltrials.gov)
    P1, N=48, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Sep 2024 --> Jan 2025
    Trial completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • EGFR mutation + ALK mutation
    |
    carboplatin • albumin-bound paclitaxel • pemetrexed
    1m
    Inadequate staging and excessive surveillance imaging: Evaluating the magnitude of benefit of targeted therapies in lung cancer. (PubMed, Eur J Cancer)
    Similarly, more frequent surveillance imaging than what is considered standard-of-care may identify disease progression earlier than what is expected in real-world clinical practice and therefore embellish the magnitude of benefit between a targeted therapy and the control arm. While targeted therapies have provided clinical benefit for individuals with oncogenic driven NSCLC, physicians and patients must be cognizant that clinical trial deviations from standard-of-care imaging practices may have embellished the magnitude of benefit for several of these therapies.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK mutation • EGFR mutation + ALK mutation
    4ms
    The Characteristics of Plasma Sample NGS Analysis in the Detection of Lung Cancer Driver Genes (IASLC-WCLC 2024)
    Only a few driver mutations were detected exclusively in plasma samples. Characteristics of detected driver genes by NGS analysis Tissue Plasma EGFR 63 37 ALK 11 2 ROS1 8 4 BRAF 5 3 MET 8 3 RET 4 3 KRAS-G12C 13 9 HER2 4 6
    PD(L)-1 Biomarker • IO biomarker • Next-generation sequencing
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • KRAS G12C • ALK mutation • KRAS G12 • EGFR mutation + ALK mutation
    |
    Oncomine Precision Assay
    10ms
    STAR-121: A Phase III Randomized Study of Domvanalimab and Zimberelimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Untreated Metastatic Non-Small Cell Lung Cancer With No Actionable Gene Alterations. (PubMed, Clin Lung Cancer)
    Enrollment in the STAR-121 study commenced on October 12, 2022, and is currently ongoing with completion planned by September 2024. The study completion is expected by December 2027.
    P3 data • Journal • Combination therapy • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    PD-L1 expression • EGFR mutation • ALK mutation • EGFR mutation + ALK mutation
    |
    Keytruda (pembrolizumab) • Yutuo (zimberelimab) • domvanalimab (AB154)
    10ms
    Study of CTDNA Response Adaptive Immuno-Chemotherapy in NSCLC (clinicaltrials.gov)
    P2/3, N=230, Recruiting, Canadian Cancer Trials Group | Active, not recruiting --> Recruiting | Phase classification: P2 --> P2/3 | N=50 --> 230 | Trial completion date: Jul 2024 --> Jul 2027 | Trial primary completion date: Dec 2023 --> Dec 2026
    Enrollment open • Phase classification • Enrollment change • Trial completion date • Trial primary completion date • Circulating tumor DNA
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • EGFR mutation + ALK mutation
    |
    Keytruda (pembrolizumab)
    1year
    Clinical Challenge of Two Competing Targetable Mutations in Non-Small-Cell Lung Cancer: A Case Report. (PubMed, Diagnostics (Basel))
    We herein present an interesting case following the course of progression of a patient with synchronous lung cancers with a discordant mutation profile. The importance of this modality in the follow-up of lung cancer patients is illustrated, and the therapeutic implications of coexisting oncogenic drivers are briefly discussed.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK rearrangement • ALK mutation • EGFR mutation + ALK mutation
    1year
    Examining the Effect of ALK and EGFR Mutations on Survival Outcomes in Surgical Lung Brain Metastasis Patients. (PubMed, Cancers (Basel))
    Although the sample size of patients receiving targeted therapies was limited, the study highlighted improved overall survival and progression-free survival rates compared to earlier trials, suggesting advancements in systemic lung metastasis treatment. The study suggests that as more targeted therapies emerge, the prospects for increased overall survival and progression-free survival in lung brain metastasis patients will likely improve.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • EGFR amplification • ALK rearrangement • ALK mutation • ALK amplification • EGFR mutation + ALK mutation
    1year
    Molecular heterogeneity of Primary liver carcinomas: early study (ECP 2023)
    HCC CK19+/CK7+ targeted therapy might benefit from a CTNNB1, TP53, ALK, EGFR, MAP2K2, RET, PTEN, and IDH2 panel, standardized for PLC spectrum. This knowledge would allow better understanding the clinical course and PLC heterogeneity, together with improving tumor classification and treatment.
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • FGFR4 (Fibroblast growth factor receptor 4) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • MAP2K2 (Mitogen-activated protein kinase kinase 2) • KRT19 (Keratin 19)
    |
    TP53 mutation • EGFR mutation • PIK3CA mutation • KIT mutation • ALK mutation • AR mutation • PDGFRA mutation • ERBB3 mutation • EGFR mutation + PIK3CA mutation • EGFR mutation + ALK mutation
    |
    Oncomine Precision Assay
    over1year
    Clinical Study to Molecularly Profile Filipino Lung Adenocarcinoma (IASLC-WCLC 2023)
    Filipino patients with lung adenocarcinoma albeit small in sample size, have remarkable diversity in molecular profile while confirming reported EGFR and ALK values. CTC values were generally low despite being at advanced stages. CD133, KRT19 and MUC1 expression were detected in half of the samples and may find diagnostic and therapeutic utility.
    Clinical
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MUC1 (Mucin 1) • KRT19 (Keratin 19)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • ALK positive • ALK mutation • EGFR G719X • EGFR exon 18 mutation • MUC1 expression • CD133 expression • EGFR mutation + ALK mutation
    over1year
    Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC (clinicaltrials.gov)
    P1, N=48, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Jun 2023 --> Jun 2024
    Trial completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • EGFR mutation + ALK mutation
    |
    carboplatin • albumin-bound paclitaxel • pemetrexed
    over1year
    Treatment patterns and outcomes of patients with metastatic non-small cell lung cancer in five European countries: a real-world evidence survey. (PubMed, BMC Cancer)
    Real-world treatment patterns suggest that chemotherapy use remains high despite guidelines recommending immunotherapy-based 1L treatment for mNSCLC. QoL reported by patients was generally lower than population reference values. Not implying causality, 1L immunotherapy use was higher during COVID-19 than pre-COVID-19, and the UK saw the biggest impact to patient management due to COVID-19.
    Journal • HEOR • Real-world evidence • PD(L)-1 Biomarker • IO biomarker • Real-world • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • EGFR wild-type • ALK mutation • ALK wild-type • EGFR wild-type + ALK wild-type • EGFR mutation + ALK mutation
    over1year
    Investigation of EGFR and ALK mutation frequency and treatment results in advanced non-small cell lung cancer. (PubMed, J Cancer Res Ther)
    Patients with EGFR and ALK mutations had a longer life expectancy than those without the mutation. It was observed that testing patients diagnosed with advanced-stage NSCLC for genetic mutations of the tumor in the first step of the treatment and initiating treatment in patients with mutations provided a significant survival advantage.
    Journal • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK mutation • EGFR exon 18 mutation • EGFR mutation + ALK mutation
    over1year
    Study of Molecular Response Adaptive Immuno-Chemotherapy in Patients With NSCLC (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, Canadian Cancer Trials Group | Trial completion date: Jul 2023 --> Jul 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • EGFR mutation + ALK mutation
    |
    Keytruda (pembrolizumab)
    over1year
    Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1. (PubMed, J Med Econ)
    In the probabilistic sensitivity analysis, 90% of the simulations performed showed that is adjuvant atezolizumab is cost-effective versus BSC considering a threshold of €30,000/QALY. Our results showed that adjuvant treatment with atezolizumab in patients with early-stage resected NSCLC with overexpression of PD-L1 and without EGFR and ALK mutations is cost-effective versus BSC as the ICERs and ICURs obtained are below the cost-effectiveness thresholds commonly considered in Spain, thus offering a new treatment alternative for these patients.
    Journal • HEOR • PD(L)-1 Biomarker • IO biomarker • Cost-effectiveness • Cost effectiveness
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    ALK rearrangement • EGFR mutation + ALK mutation • EGFR rearrangement
    |
    Tecentriq (atezolizumab)
    over1year
    Survival outcomes and prognostic factors of lung cancer patients with the MET exon 14 skipping mutation: A single-center real-world study. (PubMed, Front Oncol)
    Stage IV PSC patients with or without the METex14 mutations had similarly poor overall survival. Pemetrexed-based chemotherapy, strong c-MET ICH staining, initial brain metastasis, and lung radiotherapy, may help predict survival outcomes in patients with advanced lung ADCs harboring the METex14 mutation.
    Journal • Real-world evidence • Real-world
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • MET exon 14 mutation • ALK mutation • EGFR mutation + ALK mutation
    |
    pemetrexed
    almost2years
    Lung Cancer in Non-Smokers: Clinicopathological and Survival Differences from Smokers. (PubMed, Cureus)
    They were more often young, diagnosed at an advanced stage, with predominantly adenocarcinoma histology, and had a threefold higher frequency of EGFR mutations than smokers. In our cohort, non-smokers appear to be a targetable group with better survival than smokers.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK rearrangement • EGFR mutation + ALK mutation
    almost2years
    Risk of thromboembolism in non-small-cell lung cancers patients with different oncogenic drivers, including ROS1, ALK, and EGFR mutations. (PubMed, ESMO Open)
    Although ROS1+ and ALK+ NSCLCs had a higher cumulative incidence of TE than EGFR+ NSCLC, the person-year incidence rates were similar among the three groups. EGFR-mutated NSCLC had more arterial events. Nevertheless, ALK+ lung cancer had higher venous events than EGFR-mutated lung cancer.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • ALK positive • ALK mutation • ROS1 positive • EGFR positive • EGFR mutation + ALK mutation
    almost2years
    CAPAP-lung: Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma (clinicaltrials.gov)
    P2, N=63, Active, not recruiting, Hunan Cancer Hospital | Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Jan 2023 --> May 2023
    Enrollment closed • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    ALK mutation • EGFR negative • EGFR mutation + ALK mutation
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    almost2years
    CAPAP-lung: Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma (clinicaltrials.gov)
    P2, N=63, Enrolling by invitation, Hunan Cancer Hospital | Not yet recruiting --> Enrolling by invitation | Trial primary completion date: Jul 2021 --> Jan 2023
    Enrollment open • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    ALK mutation • EGFR negative • EGFR mutation + ALK mutation
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    almost2years
    Prognostic value of Beclin 1, EGFR and ALK in non-squamous non-small cell lung cancer. (PubMed, Discov Oncol)
    Our data indicate that Beclin 1, EGFR and ALK genes are associated with the prognosis of patients with non-squamous NSCLC. High Beclin 1 expression and negative EGFR and ALK mutations predict a poor prognosis with PFS.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • BECN1 (Beclin 1)
    |
    ALK positive • EGFR expression • ALK rearrangement • EGFR positive • EGFR negative • EGFR mutation + ALK mutation • EGFR rearrangement
    2years
    The Clinical Significance of Deglycosylated PD-L1 Level Detection Using 28-8 Monoclonal Antibody in Lung Adenocarcinoma. (PubMed, Int J Gen Med)
    PD-L1 deglycosylation enhances the detection of PD-L1 when utilizing a 28-8 antibody. Moreover, the response to deglycosylation of PD-L1 may predict the survival of certain patients with lung adenocarcinoma.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • EGFR mutation • EGFR expression • ALK mutation • EGFR mutation + ALK mutation
    |
    PD-L1 IHC 28-8 pharmDx
    2years
    Differentiating EGFR from ALK mutation status using radiomics signature based on MR sequences of brain metastasis. (PubMed, Eur J Radiol)
    T2-FLAIR and T1-CE radiomics models that can be used as noninvasive tools for identifying EGFR and ALK mutation status are helpful to guide therapeutic strategies.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK rearrangement • ALK mutation • EGFR mutation + ALK mutation
    2years
    Monitoring Circulating Tumor DNA in Untreated Non-Small-Cell Lung Cancer Patients. (PubMed, Int J Mol Sci)
    The natural course of NSCLC progression can be monitored by measuring ctDNA levels. Detection of ctDNA at diagnosis can predict development of new metastasis, rapid tumor growth and poor survival of NSCLC patients.
    Journal • Circulating tumor DNA
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK mutation • EGFR mutation + ALK mutation
    2years
    WITHDRAWN: Scenario Analysis of Budget Impact of Comprehensive Genomic Profiling (CGP) Use in Advanced NSCLC in Taiwan (ISPOR-EU 2022)
    CGP reimbursement for all advanced NSCLC would have less budget impact than for the subgroup of wild type patients while yielding more life year gained.
    HEOR
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • ALK mutation • EGFR mutation + ALK mutation
    2years
    IMPORTANCE of PRETREATMENT 18F-FDG PET/CT TEXTURE ANALYSIS in PREDICTING EGFR and ALK MUTATION in PATIENTS with NON-SMALL CELL LUNG CANCER. (PubMed, Nuklearmedizin)
    In our study, we created prediction models based on radiomic analysis of 18F-FDG PET/CT images. Tissue analysis with ML algorithms are non-invasive methods for predicting ALK rearrangement and EGFR mutation status in NSCLC, which may be useful for targeted therapy selection in a clinical setting.
    Journal • FDG PET
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK rearrangement • ALK mutation • EGFR mutation + ALK mutation
    over2years
    Association Between EGFR and ALK Mutation Status on Patient-Reported Symptoms After Palliative Radiation for Bone Pain in NSCLC. (PubMed, JTO Clin Res Rep)
    ALK+ mutation status was associated with a higher rate of complete response compared with WT (OR = 5.2, p = 0.031). There was an association between EGFR+ and ALK+ tumors and increased rates of partial pain response to palliative radiotherapy.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK rearrangement • EGFR wild-type • ALK mutation • ALK wild-type • EGFR wild-type + ALK wild-type • EGFR mutation + ALK mutation
    over2years
    Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC (clinicaltrials.gov)
    P1, N=48, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Jun 2022 --> Jun 2023
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • EGFR mutation + ALK mutation
    |
    carboplatin • albumin-bound paclitaxel • pemetrexed
    over2years
    Study of Molecular Response Adaptive Immuno-Chemotherapy in Patients With NSCLC (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, Canadian Cancer Trials Group | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • EGFR mutation + ALK mutation
    |
    Keytruda (pembrolizumab)
    over2years
    Evolving trends in lung cancer: Epidemiology, diagnosis, and management. (PubMed, Indian J Cancer)
    Although chemotherapy and molecular-targeted therapies have greatly improved the clinical outcomes, prolonged disease control could not be attained in most NSCLC patients. In this situation, immunotherapy seems to be potentially beneficial to obtain long-lasting disease control with minimal adverse events or safety concerns.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK mutation • EGFR mutation + ALK mutation • PD-L1 mutation
    over2years
    Study of Molecular Response Adaptive Immuno-Chemotherapy in Patients With NSCLC (clinicaltrials.gov)
    P2, N=50, Recruiting, Canadian Cancer Trials Group | Trial completion date: Sep 2022 --> Jul 2023 | Trial primary completion date: Jan 2022 --> Dec 2022
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • EGFR mutation + ALK mutation
    |
    Keytruda (pembrolizumab)
    over2years
    Catechol estrogen profiles of patients with EGFR- and ALK-positive non-small cell lung cancer (NSCLC) (AACR 2022)
    Targeting CYP1B1 may be of preventive and therapeutic interest. Recruitment of study participants is ongoing to validate these early findings in a larger cohort.(Supported by an In Vino Vita Award from Fox Chase Cancer Center)
    Clinical
    |
    EGFR (Epidermal growth factor receptor) • ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • CYP1A1 (Cytochrome P450 Family 1 Subfamily A Member 1) • CYP1B1 (Cytochrome P450 Family 1 Subfamily B Member 1)
    |
    EGFR mutation • ALK positive • ALK mutation • EGFR mutation + ALK mutation
    almost3years
    Combined large cell neuroendocrine carcinoma: clinical characteristics, prognosis and postoperative management. (PubMed, Eur J Cardiothorac Surg)
    LCNEC/AD was the most common type of C-LCNEC, and there were many differences between different combined components. Adjuvant chemotherapy, especially etoposide-based chemotherapy, was a beneficial option for resected C-LCNEC.Subj collection: 152.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK mutation • EGFR mutation + ALK mutation
    |
    etoposide IV
    almost3years
    Comprehensive analysis of PD-L1 in non-small cell lung cancer with emphasis on survival benefit, impact of driver mutation and histological types, and archival tissue. (PubMed, Thorac Cancer)
    There were a trend or significant differences in PD-L1 expression between different histological types in NSCLC, different EGFR and ALK status, and different tumor tissue storage time. A higher survival benefit was observed in no PD-L1 expression than with PD-L1 expression in adenocarcinoma, EGFR and ALK mutation patients. We recommend that PD-L1 assay should be performed as early as possible if tissue is available.
    Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • EGFR mutation • EGFR expression • EGFR wild-type • ALK mutation • EGFR mutation + ALK mutation
    almost3years
    Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations. (PubMed, BMC Cancer)
    ALK and EGFR mutations coincide at a relatively low frequency in lung cancer patients. ALK mutations developed either synchronously or heterochronously with EGFR mutations. Two ALK mutations (L1152R and STRN-ALK) may co-exist with EGFR mutations at a higher frequency than others. Most EGFR/ALK co-alteration patients (other than the EGFR/ALK L1152R type) can benefit from first line EGFR-TKIs.
    Clinical • Retrospective data • Journal
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4) • STRN (Striatin)
    |
    EGFR mutation • EGFR L858R • ALK positive • EGFR T790M • ALK mutation • EGFR S768I • EGFR G719C • ALK L1152R • EGFR mutation + ALK mutation
    |
    Tagrisso (osimertinib) • gefitinib
    3years
    AdvanTIG-301: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) + tislelizumab (TIS) + concurrent chemoradiotherapy (cCRT) followed by OCI + TIS or TIS + cCRT followed by TIS vs cCRT followed by durvalumab (DUR) in previously untreated, locally advanced, unresectable NSCLC (ESMO-IO 2021)
    Legal entity responsible for the study BeiGene Ltd. Funding BeiGene Ltd.
    PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    PD-L1 expression • EGFR mutation • ALK mutation • EGFR mutation + ALK mutation
    |
    Imfinzi (durvalumab) • Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    3years
    Outcomes of BRAF, MET, RET, and ROS1 Mutated Non-Small Cell Lung Cancer With Brain Metastases (NSCLCBM). (PubMed, Int J Radiat Oncol Biol Phys)
    Molecular mutations continue to be a topic of great interest in the field of NSCLCBM. These molecular mutations function as both prognostic predictors and druggable targets. Our retrospective study showed improved mPFS in patients with BRAF and MET mutations when compared to RET and ROS mutated patients and improved mOS in patients with MET mutations when compared to patients with RET mutations. However, due to the small sample size and the fact that these mutations are not mutually exclusive, it is difficult to determine statistical significance. Further studies need to be completed with larger sample sizes to determine outcomes in isolated mutations.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • BRAF mutation • ALK positive • RET fusion • ALK mutation • RET mutation • ROS1 fusion • ROS1 positive • ROS1 rearrangement • MET mutation • RET rearrangement • ROS1 mutation • EGFR mutation + ALK mutation • RET positive
    over3years
    SAKK 19/16: Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC. (clinicaltrials.gov)
    P1, N=18, Completed, Swiss Group for Clinical Cancer Research | Active, not recruiting --> Completed | Trial completion date: Oct 2021 --> Jul 2021 | Trial primary completion date: Oct 2021 --> Jul 2021
    Clinical • Trial completion • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK mutation • KRAS exon 2 mutation • EGFR mutation + ALK mutation
    |
    cisplatin • Mektovi (binimetinib) • pemetrexed
    over3years
    SPP1 overexpression is associated with poor outcomes in ALK fusion lung cancer patients without receiving targeted therapy. (PubMed, Sci Rep)
    Significant overexpression of SPP1 protein in ALK-positive lung cancer was confirmed by IHC compared to paired adjacent normal tissues and ALK-negative cancers. Thus we concluded that SPP1 overexpression is associated with poor outcomes for patients with ALK fusion lung cancer without receiving targeted therapy and PI3K/AKT/SPP1 pathway may become the promising targets in patients with aggressive lung cancer.
    Clinical • Journal
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • SPP1 (Secreted Phosphoprotein 1)
    |
    EGFR mutation • ALK positive • ALK rearrangement • ALK fusion • ALK negative • EGFR mutation + ALK mutation
    over3years
    Study of Molecular Response Adaptive Immuno-Chemotherapy in Patients With NSCLC (clinicaltrials.gov)
    P2, N=50, Recruiting, Canadian Cancer Trials Group | Trial completion date: Dec 2022 --> Sep 2022
    Clinical • Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • EGFR mutation + ALK mutation
    |
    Keytruda (pembrolizumab)